Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy : evidence from a randomized, placebo-controlled trial by K.P. Perrett et al.
Vaccine 38 (2020) 2095–2104Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc ineImmunogenicity, transplacental transfer of pertussis antibodies
and safety following pertussis immunization during pregnancy:
Evidence from a randomized, placebo-controlled trialhttps://doi.org/10.1016/j.vaccine.2019.10.105
0264-410X/ 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Abbreviations: AE, adverse event; ATP, according-to-protocol; CI, confidence interval; ELISA, enzyme-linked immunosorbent assays; FHA, filamentous hemag
GMC, geometric mean concentration; ICF, informed consent form; LL, lower limit; LLoQ, lower limit of quantitation; PRN, pertactin; PT, pertussis toxoid; SAE, serious
event; Tdap, diphtheria-tetanus-acellular pertussis vaccine; TVC, total vaccinated cohort; UK, United Kingdom; US, United States.
⇑ Corresponding author at: GSK, Avenue Fleming 20, 1300 Wavre, Belgium.
E-mail addresses: kirsten.perrett@rch.org.au (K.P. Perrett), scott.halperin@dal.ca (S.A. Halperin), t.nolan@unimelb.edu.au (T. Nolan), b.tapiero@umontreal.ca (B.
federico.martinon.torres@sergas.es (F. Martinón-Torres), z.stranak@seznam.cz (Z. Stranak), miia.virta@staff.uta.fi (M. Virta), ovanderk@ucalgary.ca (O.G. Van
kosinpav@seznam.cz (P. Kosina), icristobalg@sego.es (I. Cristobal García), gianvincenzo.zuccotti@unimi.it (G.V. Zuccotti), lusine.x.kostanyan@gsk.com (L. Kostanyan)
meyer@gsk.com (N. Meyer), maria-angeles.x.ceregido@gsk.com (M.A. Ceregido), brigitte.cheuvart@gsk.com (B. Cheuvart), sherine.o.kuriyakose@gsk.com (S.O. Kur
mmarcos@egom.es (M. Marcos Fernández), eloyasenjo@telefonica.net (J.E. Asenjo de la Fuente), paola.marchisio@unimi.it (P.G. Marchisio), narcisa.x.mesaros@
(N. Mesaros).Kirsten P. Perrett a, Scott A. Halperin b, Terry Nolan a, Cristina Martínez Pancorbo c, Bruce Tapiero d,
Federico Martinón-Torres e, Zbynek Stranak f, Miia Virta g, Otto G. Vanderkooi h, Pavel Kosina i,
Maria Begoña Encinas Pardilla j, Ignacio Cristobal García k, Gian Vincenzo Zuccotti l, Lusine Kostanyanm,
Nadia Meyer n, Maria Angeles Ceregido n, Brigitte Cheuvart n, Sherine O. Kuriyakose o,
Manuel Marcos Fernández p, Miguel Ángel Rodríguez Zambrano q, Adrián Martín García r,
Juan Eloy Asenjo de la Fuente s, Maria Dolores Camacho Marín s, María de la Calle Fernández-Miranda t,
Yolanda Romero Espinar u, Paola Giovanna Marchisio v, Paolo Manzoni w, Narcisa Mesaros n,⇑
aMurdoch Children’s Research Institute and Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia
bDalhousie University, Canadian Center for Vaccinology, Halifax, Canada
c Instituto Sevillano de la Mujer-Instituto Hispalense de Pediatría, Seville, Spain
dCHU Sainte Justine, Université de Montréal, Montréal, Canada
e Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela and Genetics, Vaccines and Pediatrics Research
Group, University of Santiago de Compostela, Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain
f Institute for the Care of Mother and Child, Prague, Czech Republic
g Tampere Vaccine Research Center, Tampere University, Tampere, Finland
hAlberta Children’s Hospital, University of Calgary, Alberta, Calgary, Canada
iUniversity Hospital, Hradec Kralove, Czech Republic
jHospital Universitario Puerta de Hierro, Majadahonda, Spain
kUniversidad Francisco de Vitoria, Madrid, Spain
lOspedale dei Bambini Vittore Buzzi and University of Milan, Milan, Italy
mModis, C/O GSK, Wavre, Belgium
nGSK, Wavre, Belgium
oGSK, Bangalore, India
pHospital Monteprincipe, Boadilla del Monte, Spain
qHospital HM Puerta del Sur, Móstoles, Spain
rNuevo Hospital Universitario de Burgos, Burgos, Spain
sHospital Clínico San Carlos, Madrid, Spain
tHospital La Paz, Madrid, Spain
uHospital Quirónsalud Málaga, Málaga, Spain
vUniversità degli Studi di Milano, Milan, Italy
wOspedale Ostetrico Ginecologico Sant’Anna, Turin, Italy and Department of Maternal-Infant-Pediatric Health, Degli Infermi Hospital, Biella, Italyglutinin;
adverse
Tapiero),
derkooi),
, nadia.x.
iyakose),
gsk.com
2096 K.P. Perrett et al. / Vaccine 38 (2020) 2095–2104a r t i c l e i n f oArticle history:
Received 30 July 2019
Received in revised form 30 October 2019
Accepted 31 October 2019
Available online 24 November 2019
Keywords:
Tdap
Adult formulation acellular pertussis
vaccine
Maternal immunizationa b s t r a c t
Background: Pertussis immunization during pregnancy is recommended in many countries. Data from
large randomized controlled trials are needed to assess the immunogenicity, reactogenicity and safety
of this approach.
Methods: This phase IV, observer-blind, randomized, placebo-controlled, multicenter trial assessed
immunogenicity, transplacental transfer of maternal pertussis antibodies, reactogenicity and safety of
a reduced-antigen-content diphtheria-tetanus-three-component acellular pertussis vaccine (Tdap) dur-
ing pregnancy. Women received Tdap or placebo at 27–36 weeks’ gestation with crossover  72-hour-
postpartum immunization. Immune responses were assessed before the pregnancy dose and 1 month
after, and from the umbilical cord at delivery. Superiority (primary objective) was reached if the lower
limits of the 95% confidence intervals (CIs) of the pertussis geometric mean concentration (GMC) ratios
(Tdap/control) in cord blood were  1.5. Solicited and unsolicited adverse events (AEs) and pregnancy-/
neonate-related AEs of interest were recorded.
Results: 687 pregnant women were vaccinated (Tdap: N = 341 control: N = 346). Superiority of the per-
tussis immune response (maternally transferred pertussis antibodies in cord blood) was demonstrated
by the GMC ratios (Tdap/control): 16.1 (95% CI: 13.5–19.2) for anti-filamentous hemagglutinin, 20.7
(15.9–26.9) for anti-pertactin and 8.5 (7.0–10.2) for anti-pertussis toxoid. Rates of pregnancy-/
neonate-related AEs of interest, solicited general and unsolicited AEs were similar between groups.
None of the serious AEs reported throughout the study were considered related to maternal Tdap vacci-
nation.
Conclusions: Tdap vaccination during pregnancy resulted in high levels of pertussis antibodies in cord
blood, was well tolerated and had an acceptable safety profile. This supports the recommendation of
Tdap vaccination during pregnancy to prevent early-infant pertussis disease.
Clinical Trial Registration. ClinicalTrials.gov: NCT02377349.
 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction 2. MethodsPertussis (Bordetella pertussis), a highly contagious acute respi-
ratory tract infection, remains a particular and potentially life-
threatening burden for infants too young to be vaccinated [1,2].
To combat a sustained increase in pertussis disease morbidity
and mortality in infants in the United States (US), United Kingdom
(UK), Australia and other countries from 2008 to 2012 [2], innova-
tive strategies to complement the widespread national childhood
immunization programs were urgently pursued. Cocooning, a
strategy of indirect protection where postpartum mothers and
others in close contact with infants are vaccinated, was imple-
mented as an emergency measure in several countries [2–4]. An
alternate strategy of direct protection via neonatal immunization
has also shown promise in some clinical trials [5–7]. However,
because of the difficulty in successfully implementing complex
cocoon strategies [8,9] and the existence of a neonatal susceptibil-
ity gap before a sufficient immune response is achieved with the
birth-dose approach [7], maternal immunization has become the
most commonly implemented strategy [4].
Immunization during pregnancy provides passive protection to
the newborn via transfer of maternal antibodies through the pla-
centa and indirect protection by preventing pertussis in the mother
[10,11]. In 2011, the US became the first country to recommend
pregnant women to be vaccinated with a pertussis-containing vac-
cine [12]. The following year, the UK introduced a temporary emer-
gency maternal pertussis immunization program [13]. These
pivotal maternal immunization recommendations were imple-
mented with limited direct evidence of the efficacy or safety of this
approach [10].
In this randomized placebo-controlled trial, we examined the
immunogenicity of a reduced-antigen-content diphtheria-
tetanus-acellular pertussis vaccine (Tdap) administered during
the third trimester of pregnancy, the transplacental transfer of
maternal pertussis antibodies and the safety of Tdap vaccination
for the mother, fetus and neonate.2.1. Study design and participants
This phase IV, multi-center, observer-blind, randomized,
placebo-controlled, crossover trial was conducted between 14
October 2015 and 24 October 2017 in Australia, Canada, Czech
Republic, Finland, Italy and Spain. The trial (ClinicalTrials.gov:
NCT02377349) was conducted according to the principles of Good
Clinical Practice, the Declaration of Helsinki and applicable regula-
tions. The centers’ Institutional Review Boards and/or Ethics Com-
mittees (Supplementary material) approved the protocol and
informed consent form. An independent data monitoring commit-
tee oversaw the participants’ and their fetuses’/newborns’ safety.
Weenrolledhealthywomen18–45 yearsold, at270/7–366/7weeks’
gestation (asestablishedbyultrasoundexamination),whowerenotat
known risk of pregnancy-related complications andhada normal sin-
gleton pregnancy. Exclusion criteria included previous vaccination
withdiphtheria (toxoid), tetanus (toxoid) or pertussis antigensduring
the current pregnancy; history of physician-diagnosed or laboratory-
confirmedpertussiswithin thepast5 years; chronicadministrationof
immune-modifying drugs; immunosuppressive or other serious
underlying medical conditions; and immunization within 30 days
before/after study vaccine administration (except seasonal influenza
vaccine). Detailed inclusion and exclusion criteria are provided in
the Supplementary methods. Each participant provided written
informed consent before enrollment.2.2. Randomization and blinding
We randomized women (1:1) to a Tdap group and a control
(placebo) group. Allocation of participants was performed at the
study centers using a central internet-based randomization sys-
tem. The randomization algorithm used center, age (18–24 years,
25–34 years, 35–45 years), gestational age at vaccination (27–
K.P. Perrett et al. / Vaccine 38 (2020) 2095–2104 209732 weeks, 33–36 weeks) and country as minimization factors, each
having an equal weight in the algorithm.
Data were collected in an observer-blind manner: the partici-
pants and study personnel responsible for evaluating the study
endpoints and for laboratory testing were unaware of the vaccine
given. Vaccines were prepared and administered by study person-
nel not involved in the analyses.2.3. Procedures
Women in the Tdap group received a single reduced-antigen-
content Tdap dose at 27–36 weeks’ gestation (visit 1) and a placebo
dose  72 h post-delivery (visit 3); women in the control group
received the reverse—placebo at 27–36 weeks’ gestation and Tdap
post-delivery (Fig. 1). Each Tdap dose (Boostrix, GSK) con-
tained  2 IU diphtheria toxoid,20 IU tetanus toxoid, 8 mg pertus-
sis toxoid (PT), 8 mg filamentous hemagglutinin (FHA), 2.5 mg
pertactin (PRN) and 500 mg Al3+. Each placebo dose contained
150 mM NaCl. Both were injected intramuscularly in the deltoid
muscle of the non-dominant arm. Eight different commercial lots
of Tdap vaccine were used (Supplementary material).
Blood samples were collected from all women before and
1 month (allowed interval: 21–48 days) after the pregnancy dose
(~5 mL) and from the umbilical cord at delivery (~2.5 mL) (Fig. 1).
Antibodies to the Tdap antigens were quantified at GSK, Rixen-
sart/Wavre, Belgium using validated enzyme-linked immunosor-
bent assays (ELISAs). Assay cut-offs (lower limits of quantitation)
were 0.057 IU/mL (anti-diphtheria), 0.043 IU/mL (anti-tetanus),
2.046 IU/ml (anti-FHA), 2.187 IU/ml (anti-PRN) and 2.693 IU/mL
(anti-PT). Seroprotection against diphtheria and tetanus was
defined as an antibody concentration  0.1 IU/mL [14,15]. No cor-
relate of protection has been established for pertussis [16].
At each vaccination visit (visits 1 and 3, Fig. 1), participants
received diary cards to record solicited local (injection site pain,
redness, swelling) and general (fever, headache, fatigue, gastroin-
testinal symptoms) adverse events (AEs) within 8 days and unso-
licited AEs within 31 days post-vaccination. All pregnancy- and
neonate-related AEs of interest (defined and graded as described
by Munoz et al [17]: gestational diabetes, pregnancy-related
hypertension, premature rupture of membranes, preterm prema-
ture rupture of membranes, premature labor, premature uterine
contractions, intrauterine growth restriction/poor fetal growth,Fig. 1. Study design. Abbreviations: AE, adverse event; Tdap, reducedpre-eclampsia, eclampsia, vaginal or intrauterine hemorrhage,
maternal death, preterm birth, neonatal death, small for gesta-
tional age, neonatal hypoxic-ischemic encephalopathy, and failure
to thrive/growth deficiency) had to be recorded on the diary cards
from receipt of the first vaccine or placebo dose until study end
(visit 4, 2 months after delivery). All adverse pregnancy outcomes
(live birth with/without congenital anomalies, still birth with/
without congenital anomalies, elective termination with/without
congenital anomalies) and pregnancy- and neonate-related AEs
of interest were reported as serious adverse events (SAEs). Other
SAEs were also recorded from the first vaccine or placebo dose
until study end. If participants noticed any large injection site reac-
tions (any local swelling with diameter > 100 mm, any noticeable
diffuse injection site swelling or any noticeable increased circum-
ference of the injected limb), they had to contact the study person-
nel and visit the investigator’s office for evaluation as soon as
possible. Diary cards were collected and verified during a discus-
sion between the investigator and the participant on visits 2, 3
and 4. Any unreturned diary cards were sought from the partici-
pants through phone calls or any other convenient procedure.
The investigators assessed the intensity of all AEs and their causal
relation to vaccination. All information relevant to the (S)AEs were
recorded on an electronic case report form.2.4. Objectives
The primary objective was to demonstrate that the amount of
maternally transferred pertussis antibodies in cord blood of
Tdap-vaccinated mothers was superior to that in cord blood of
placebo-vaccinated mothers in terms of geometric mean concen-
trations (GMCs) for pertussis antibodies. Superiority was reached
if the lower limits (LLs) of the 95% confidence intervals (CIs) of
the GMC ratios (Tdap divided by control) for anti-FHA, anti-PRN
and anti-PT antibodies were  1.5.
Secondary immunogenicity objectives encompassed assessing
pertussis seropositivity rates in cord blood samples; and Tdap
immunogenicity in pregnant women in terms of seroprotection/
seropositivity rates, vaccine response (only shown here for pertus-
sis) and antibody GMCs 1 month post-vaccination.
Secondary safety objectives included assessing pregnancy out-
comes and pregnancy-/neonate-related AEs of interest until study
end (2 months after delivery); occurrence of solicited local and-antigen-content diphtheria-tetanus-acellular pertussis vaccine.
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the pregnancy and post-delivery doses; and SAEs in the mothers
and their infants throughout the study (Fig. 1).
2.5. Statistical analyses
The target sample size was 680 participants (340 per group).
Assuming a drop-out rate of 20%, this would result in 272 evalu-
able participants per group, which would provide > 96% overall
power to reach the primary objective.
The primary immunogenicity analyses were based on the
according-to-protocol (ATP) cohort for immunogenicity, including
all eligible participants who received the study vaccines per proto-
col, complied with study procedures and intervals, had the cord
blood collection at least 21 days post-vaccination and had
immunogenicity results available for at least one Tdap antigen.
For the primary superiority objective, the 95% CIs of the GMC ratios
were computed using a two-sample t test assuming heterogeneity
of variance. Seroprotection/seropositivity and vaccine response
rates were calculated with exact 95% CIs. GMCs were calculated
with 95% CIs. The definition of vaccine response for pertussis is
included in the results section (table footnote). We also performed
immunogenicity subgroup analyses by gestational age at the preg-
nancy dose.
The primary analyses for safety were based on the total vacci-
nated cohort (TVC), including all participants with documented
vaccination. Percentages of participants reporting solicited or
unsolicited AEs were calculated with exact 95% CIs. SAEs were
described in detail.
All endpoint analyses, except for the primary endpoints, were
descriptive. Statistical analyses were performed using SAS version
9.2.3. Results
3.1. Study population
725 pregnant women were enrolled, 690 were randomized, 687
(Tdap: N = 341; control: N = 346) were included in the TVC and 660
completed the study (96% of those randomized). The ATP cohort for
immunogenicity comprised 583 participants (Tdap: N = 291; con-
trol: N = 292; 84% of those randomized) (Fig. 2). Baseline character-
istics were comparable between groups (Table 1). In the TVC, the
mean gestational age at the pregnancy dose was 31.8 weeks (Tdap)
and 31.6 weeks (control). The mean time between vaccination and
delivery was 50.6 (Tdap) and 52.4 days (control) (Table 1).
3.2. Immunogenicity
The primary objective of the study was met: the amount of
maternally transferred pertussis antibodies in cord blood of
Tdap-vaccinated mothers was superior to that in cord blood of con-
trol mothers because the LLs of the 95% CIs of the anti-FHA, anti-
PRN and anti-PT GMC ratios (Tdap/control) were  1.5 (Table 2).
GMCs for maternally transferred pertussis antibodies in cord blood
were 8.5–20.7-fold higher for Tdap-vaccinated than for control
mothers.
Similarly, anti-FHA, anti-PRN and anti-PT antibody GMCs in
Tdap-vaccinated pregnant women were 11.1–27.0-fold higher
than in controls 1 month after the pregnancy dose (Table 3).
Post-vaccination antibody GMCs and seropositivity rates in preg-
nant women were similar to those in cord blood samples for the
respective groups (with a > 1 ratio of cord blood to maternal anti-
body GMCs) (Tables 2 and 3). One month after the pregnancy dose,
93.4%, 89.6% and 87.8% of women in the Tdap group mounted avaccine response against FHA, PRN and PT, respectively, compared
to  1.4% in the control group (Table 3).
When analyzing the pertussis immune response by gestational
age at the pregnancy dose, higher anti-PRN antibody GMCs were
observed in infant cord blood from mothers vaccinated at 27–
32 weeks’ compared to 33–36 weeks’ gestation (Table 4).
One month after the pregnancy dose, 97.6% and 100% of women
in the Tdap group were seroprotected against diphtheria and teta-
nus, respectively, compared to 70.6% and 96.6% in the control
group (Table 5). Anti-diphtheria and anti-tetanus antibody GMCs
increased after Tdap vaccination and were 8.6–9.5-fold higher in
the Tdap than in the control group (Table 5).3.3. Reactogenicity and safety
Compliance in returning diary cards in the Tdap group was
98.2% after the pregnancy dose and 96.4% after the post-delivery
dose (for solicited and unsolicited AEs); in the control group, com-
pliance was 98.8% and 99.1% after the pregnancy dose and 96.8%
and 96.5% after the post-delivery dose (for solicited and unsolicited
AEs, respectively).
341 pregnancies in the Tdap and 345 in the control group
resulted in live births; congenital anomalies were reported for 9
infants (2.6%) in the Tdap and 8 (2.3%) in the control group (Table 6
and Supplementary Table 1). One woman in the control group was
lost to follow-up before delivery.
Pregnancy-/neonate-related AEs of interest were reported at
similar rates in both groups, the most common being premature
labor (Tdap: 3.8%; control: 3.2%) and premature rupture of mem-
branes (Tdap: 3.8%; control: 4.3%) (Table 6). Eleven infants (3.2%)
in the Tdap group and nine (2.6%) in the control group were born
prematurely. There were no maternal or neonatal deaths. At birth,
the infants’ mean gestational age, weight and Apgar scores were
comparable between groups (Tables 1 and 6).
Pain was the most commonly reported solicited local AE after
the pregnancy and post-delivery doses (Table 7). Solicited general
AEs were reported at similar rates in both groups after the preg-
nancy dose and after the post-delivery dose (Table 7). Solicited
AEs were mostly mild or moderate (Table 7). There were no reports
of large injection site reactions within 8 days after either dose. The
incidence of unsolicited AEs was similar in both groups after the
pregnancy and post-delivery doses, for the mothers (Table 7) and
their infants (Supplementary table 2).
Between the pregnancy and post-delivery doses, 45 women
(13.2%) in the Tdap group reported 56 SAEs and 48 women
(13.9%) in the control group reported 64 SAEs (Supplementary
table 3). One of these SAEs (premature labor in a woman in the
control group) was assessed as related to (placebo) vaccination.
There were two cases of chorioamnionitis in the control and none
in the Tdap group. Between the post-delivery dose and study end,
eight women (2.4%) in the Tdap group reported eight SAEs and five
women (1.5%) in the control group reported six SAEs (Supplemen-
tary table 4).
77 SAEs were reported for 52 infants (15.2%) in the Tdap group
and 63 SAEs for 45 infants (13.0%) in the control group (Supple-
mentary table 1). None of the SAEs in infants were assessed as
maternal Tdap vaccination-related; one (respiratory distress in
an infant in the Tdap group, Fig. 2) led to a withdrawal.
Supplementary Fig. 1 summarizes these findings and highlights
their clinical relevance.4. Discussion
Maternal pertussis immunization has undergone a paradigm
shift in recent years as evidence emerges of robust effectiveness
Total enrolled cohort
N=725
Total vaccinated cohort
N=341
Total vaccinated cohort
N=346
Withdrawn (n=16)
Serious adverse event (n=1)
Protocol violation (n=3)
Consent withdrawn (n=5)
Lost to follow-up (n=7)
Withdrawn (n=11)
Protocol violation (n=2)
Consent withdrawn (n=3)
Lost to follow-up (n=5)
Other reason (n=1)
Completed last visit
N=325
Completed last visit
N=335
ATP cohort for immunogenicity
N=291
Excluded from ATP analysis (n=50)
Randomization code broken (n=2)
Protocol violation (n=6)
Non-compliance with blood sampling schedule (n=20)
Essential serological data missing (n=22)
ATP cohort for immunogenicity
N=292
Excluded from ATP analysis (n=54)
Randomization failure (n=2)
Randomization code broken (n=5)
Protocol violation (n=3)
Non-compliance with blood sampling schedule (n=14)
Essential serological data missing (n=30)
Randomized
N=690
Excluded (n=35)
Participant number allocated but no group assigned 
(screening failure) (n=35)
Tdap group
N=344
Control group
N=346
Excluded (n=3)
Excluded from analyses (invalid ICF) (n=1)
Participant number allocated but vaccine dose not 
administered (n=2)
Fig. 2. Participant flow diagram. Abbreviations: ATP, according-to-protocol; ICF, informed consent form; N, number of participants per cohort/group; n, number of
participants with the specified elimination code assigned (excluding those for whom a lower elimination code number was assigned); Tdap, reduced-antigen-content
diphtheria-tetanus-acellular pertussis vaccine.
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pertussis [18–21]. However, performing clinical trials in pregnant
women is challenging [22], hence the vast majority of immuno-
genicity and safety data has come from observational studies,
which are prone to bias [23]. To our knowledge, only five random-
ized controlled trials (two placebo-controlled) have directly
assessed the immunogenicity and safety of pertussis vaccination
during pregnancy [24–28]. The increasing number of countries rec-ommending maternal Tdap vaccination reduces the likelihood that
additional randomized placebo-controlled trials will be performed.
With 687 vaccinated pregnant women from six countries, our trial
is currently the largest placebo-controlled randomized trial on
maternal pertussis immunization and one of two randomized con-
trolled trials to assess the three-component pertussis Tdap vaccine
administered during pregnancy [28]. Our trial has shown that Tdap
immunization during the third trimester of pregnancy was well
Table 1
Characteristics of participants in the total vaccinated cohort.
Tdap group
(N = 341)
Control group
(N = 346)
Mean age ± SD at pregnancy dose, years 32.7 ± 4.4 32.5 ± 4.3
Age category at pregnancy dose, n (%)
18–24 years 10 (2.9) 13 (3.8)
25–34 years 214 (62.8) 215 (62.1)
35–45 years 117 (34.3) 118 (34.1)
Ethnic origin, n (%)
Whitea 317 (93.0) 326 (94.2)
Asian 9 (2.6) 2 (0.6)
Other 15 (4.4) 18 (5.2)
Mean BMI ± SD, kg/m2 27.5 ± 4.4 28.2 ± 5.1
Mean gestational age at pregnancy
dose ± SD, weeks
31.8 ± 2.7 31.6 ± 2.7
Gestational age category at pregnancy dose, n (%)
<27 weeks 0 (0.0) 1 (0.3)b
27–32 weeks 204 (59.8) 200 (57.8)
33–36 weeks 136 (39.9) 145 (41.9)
>36 weeks 1 (0.3) 0 (0.0)
Mean gestational age at delivery ± SD,
weeks
39.1 ± 1.3 39.3 ± 1.2
Mean time between pregnancy dose and
delivery ± SD, days
50.6 ± 20.4 52.4 ± 19.7
Breastfeeding, n (%)
Never 12 (3.7) 23 (6.9)
No 27 (8.4) 34 (10.1)
Yes 284 (87.9) 278 (83.0)
Missing 18 11
Abbreviations: ATP, according-to-protocol; BMI, body mass index; N, total number
of participants per group and cohort; n (%), number (percentage) of participants in
the specified category; SD, standard deviation; Tdap, reduced-antigen-content
diphtheria-tetanus-acellular pertussis vaccine.
a Includes White – Caucasian/European heritage (majority) and White – Arabic/
North African heritage (3 in Tdap and 7 in control group).
b This participant was considered < 27 weeks of gestation at the pregnancy dose
for analysis, however after database freeze it was confirmed by the investigator that
the gestational age for this participant at the pregnancy dose was 27 weeks.
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AEs of interest or abnormal pregnancy outcomes, elicited strong
antibody responses in women and provided high levels of pertussis
antibodies to the newborn infant.
The primary objective of the study was achieved; the amount of
maternally transferred pertussis antibodies in cord blood of Tdap-
vaccinated mothers was superior to that in cord blood of placebo-
vaccinated mothers, with 8.5–20.7-fold higher GMCs in cord blood
of Tdap- vs placebo-vaccinated mothers. This finding is consistent
with other randomized controlled trials [24–28] and observational
(prospective or retrospective cohort) studies [29–32] that com-
pared pertussis antibody levels in cord blood of pertussis-
vaccinated mothers to cord blood of control (placebo, Td, TT orTable 2
Superiority assessment, GMCs and seropositivity rates of maternally transferred pertussis a
cohort for immunogenicity).
Antibody (LLoQ) Tdap group C
N %  LLoQ (95% CI) GMC, IU/mL (95% CI) N
Anti-FHA 29 100 366.1 2
(2.046 IU/mL) 1 (98.7–100) (329.0–407.3) 2
Anti-PRN 29 99.7 301.8 2
(2.187 IU/mL) 0 (98.1–100) (250.9–362.9) 1
Anti-PT 29 98.6 46.9 2
(2.693 IU/mL) 0 (96.5–99.6) (41.2–53.3) 2
Abbreviations: %  LLoQ, percentage of women for whom antibody concentrations in in
protocol; CI, confidence interval; FHA, filamentous hemagglutinin; GMC, geometric mea
available results; PRN, pertactin; PT, pertussis toxoid; Tdap, reduced-antigen-content di
a Superiority was reached if the lower limits of the 95% CIs of the GMC ratios (Tdap dunvaccinated) mothers. GMC ratios (Tdap/control) for pertussis
antibodies ranged from 2.7 to 22.2 (vs 8.5 in our study) for PT,
3.4 to 21.2 (vs 16.1 in our study) for FHA and 5.5 to 44.0 (vs 20.7
in our study) for PRN [24–30,32].
The immunogenicity of Tdap vaccination in pregnant women in
our study was analogous to that found in previous studies, with
consistently higher pertussis antibody concentrations after Tdap
vaccination than after control or no vaccination [24,26,30].
Although direct comparisons between studies for immunogenicity
are inherently difficult due to different laboratories and assays
used, timing of vaccination during pregnancy, study design and
other factors (e.g., epidemiological background of the study popu-
lation), these findings are reassuring. In addition, our finding of
a > 1 ratio of cord blood to maternal antibody (1 month post-
vaccination) for FHA, PT and PRN in Tdap-recipient infant-
maternal pairs and placebo-recipient pairs demonstrated an active
transport of pertussis antibodies across the placenta.
The optimal timing of maternal pertussis immunization for
antibody transfer to the fetus is a critical issue. The initial recom-
mendation in the US was vaccination between 27 and 36 weeks’
gestation while the UK elected to recommend a narrower window
between 28 and 32 weeks’ gestation (but allowing vaccination up
to 38 weeks) [12,13]. Recent observational studies have suggested
that higher anti-pertussis antibody concentrations may be
achieved in cord blood when mothers are vaccinated earlier: 27–
30 weeks’ gestation compared to later [29], 28–32 weeks’ com-
pared to 33–36 weeks’ gestation [33], or second- vs third-
trimester immunization [34]. Current recommendations vary by
country, e.g., UK: 16–32 weeks’ [35], Canada: 27–32 weeks’ [36],
US: 27–36 weeks’ [12] and Australia: 20–32 weeks’ gestation
[37]. In our trial, we found higher PRN GMCs in cord blood of moth-
ers vaccinated at 27–32 vs 33–36 weeks’ gestation. However, as
our trial was not powered for this outcome, this observation may
also be due to confounding factors.
Our large trial adds to the increasing evidence of tolerability
and safety of pertussis vaccines in pregnancy established from
large observational studies, randomized controlled trials, system-
atic reviews and meta-analyses [10,20,21,24–28,38–42]. We found
no difference between the Tdap and control groups in the occur-
rence of obstetric or fetal complications or in the reported rates
of AEs in mothers or infants. Of note, although chorioamnionitis
was not selected as an AE of interest at the beginning of our study,
during the study conduct several articles indicated a small but sig-
nificant increased risk of chorioamnionitis [21,43,44]. In our trial,
two women in the control and none in the Tdap group reported
chorioamnionitis.
Our study has some limitations. Although this large trial provides
definitive evidence for the primary outcome, it is limited by power to
provide reliable conclusions for the rare AEs following immunization
or adverse pregnancy outcomes. In addition, no adjustments for mul-ntibodies in infant cord blood of Tdap-vaccinated women versus control women (ATP
ontrol group Tdap/control
%  LLoQ (95% CI) GMC, IU/mL (95% CI) GMC ratioa (95% CI)
9 96.6 22.7 16.1
(93.8–98.3) (19.7–26.2) (13.5–19.2)
9 88.0 14.6 20.7
(83.7–91.5) (12.1–17.7) (15.9–26.9)
9 68.8 5.5 8.5
(63.2–74.1) (4.8–6.3) (7.0–10.2)
fant cord blood were greater than or equal to the assays’ LLoQs; ATP, according-to-
n concentration; LLoQ, lower limit of quantitation; N, number of participants with
phtheria-tetanus-acellular pertussis vaccine.
ivided by control) for anti-FHA, anti-PRN and anti-PT antibodies were  1.5.
Table 3
Pertussis vaccine response 1 month post-vaccination and seropositivity rates and GMCs for pertussis antibodies before and 1 month post-vaccination in pregnant women (ATP
cohort for immunogenicity).
Antibody (LLoQ) Time
point
Tdap group Control group
N Vaccine responsea%
(95% CI)
N’ %  LLoQ
(95% CI)
GMC, IU/mL
(95% CI)
N Vaccine responsea%
(95% CI)
N’ %  LLoQ
(95% CI)
GMC, IU/mL
(95% CI)
Anti-FHA
(2.046 IU/mL)
Pre – – 289 94.5
(91.2–96.8)
13.7
(11.8–15.8)
– – 291 94.5
(91.2–96.8)
15.7
(13.6–18.0)
Post 288 93.4
(89.9–96.0)
290 100
(98.7–100)
317.5
(285.0–353.8)
290 1.4
(0.4–3.5)
291 94.5
(91.2–96.8)
15.0
(13.1–17.2)
Anti-PRN
(2.187 IU/mL)
Pre – – 289 84.4
(79.7–88.4)
11.1
(9.1–13.4)
– – 290 85.2
(80.6–89.1)
11.3
(9.4–13.6)
Post 288 89.6
(85.5–92.9)
290 100
(98.7–100)
283.6
(237.1–339.1)
290 0.7
(0.1–2.5)
291 84.5
(79.9–88.5)
10.5
(8.7–12.5)
Anti-PT
(2.693 IU/mL)
Pre – – 288 58.0
(52.1–63.8)
4.0
(3.5–4.5)
– – 291 63.2
(57.4–68.8)
4.3
(3.8–4.8)
Post 287 87.8
(83.4–91.4)
289 98.6
(96.5–99.6)
45.6
(40.4–51.5)
291 1.0
(0.2–3.0)
292 61.3
(55.5–66.9)
4.1
(3.6–4.6)
Abbreviations: %  LLoQ, percentage of women with antibody concentrations greater than or equal to the assays’ LLoQs; -, not applicable; ATP, according-to-protocol; CI,
confidence interval; FHA, filamentous hemagglutinin; GMC, geometric mean concentration; LLoQ, lower limit of quantitation; N, number of participants with pre- and post-
vaccination results available; N’, number of participants with results available at the specified time point; PRN, pertactin; PT, pertussis toxoid; Tdap, reduced-antigen-content
diphtheria-tetanus-acellular pertussis vaccine.
a Vaccine response was defined as a post-vaccination antibody concentration  4 times the LLoQ for participants with a pre-vaccination antibody concentration below the
LLoQ; a post-vaccination antibody concentrations  4 times the pre-vaccination concentration for participants with a pre-vaccination antibody concentration between the
LLoQ and < 4 times the LLoQ; and a post-vaccination antibody concentration  2 times the pre-vaccination concentration for participants with a pre-vaccination antibody
concentration  4 times the LLoQ.
Table 4
Seropositivity rates and GMCs of maternally transferred pertussis antibodies in infant cord blood of Tdap-vaccinated women versus control women, by gestational age at the
pregnancy dose (ATP cohort for immunogenicity).
Antibody (LLoQ) Gestational age at pregnancy dose Tdap group Control group
N %  LLoQ (95% CI) GMC, IU/mL (95% CI) N %  LLoQ (95% CI) GMC, IU/mL (95% CI)
Anti-FHA (2.046 IU/mL) 27–32 weeks 184 100
(98.0–100)
403.6
(356.7–456.6)
172 95.3
(91.0–98.0)
20.3
(16.8–24.6)
33–36 weeks 107 100
(96.6–100)
309.6
(254.3–376.9)
119 98.3
(94.1–99.8)
26.3
(21.1–32.7)
Anti-PRN (2.187 IU/mL) 27–32 weeks 183 100
(98.0–100)
386.6
(309.7–482.5)
171 87.7
(81.8–92.2)
13.6
(10.6–17.3)
33–36 weeks 107 99.1
(94.9–100)
197.5
(144.1–270.7)
119 88.2
(81.0–93.4)
16.2
(11.9–22.0)
Anti-PT(2.693 IU/mL) 27–32 weeks 184 98.9
(96.1–99.9)
51.2
(43.6–60.0)
172 66.9
(59.3–73.8)
5.3
(4.5–6.3)
33–36 weeks 106 98.1
(93.4–99.8)
40.2
(32.3–50.1)
119 71.4
(62.4–79.3)
5.8
(4.7–7.3)
Abbreviations: %  LLoQ, percentage of women for whom antibody concentrations in infant cord blood were greater than or equal to the assays’ LLoQs; ATP, according-to-
protocol; CI, confidence interval; FHA, filamentous hemagglutinin; GMC, geometric mean concentration; LLoQ, lower limit of quantitation; N, number of participants with
available results; PRN, pertactin; PT, pertussis toxoid; Tdap, reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine.
Table 5
Seroprotection rates and GMCs for diphtheria and tetanus antibodies before and 1 month post-vaccination in pregnant women (ATP cohort for immunogenicity).
Antibody Time point Tdap group Control group
N % 0.1 IU/mL (95% CI) GMC, IU/mL (95% CI) N % 0.1 IU/mL (95% CI) GMC, IU/mL (95% CI)
Anti-diphtheria Pre 288 64.2 (58.4–69.8) 0.19 (0.16–0.22) 288 71.2 (65.6–76.3) 0.23 (0.19–0.27)
Post 290 97.6 (95.1–99.0) 2.19 (1.87–2.57) 289 70.6 (65.0–75.8) 0.23 (0.19–0.27)
Anti-tetanus Pre 289 95.8 (92.9–97.8) 0.92 (0.81–1.04) 291 96.6 (93.8–98.3) 1.05 (0.92–1.19)
Post 290 100 (98.7–100) 8.43 (7.72–9.20) 292 96.6 (93.8–98.3) 0.98 (0.86–1.11)
Abbreviations: % 0.1 IU/mL, percentage of women with antibody concentrations greater than or equal to 0.1 IU/mL (seroprotection cut-off); ATP, according-to-protocol; CI,
confidence interval; GMC, geometric mean concentration; N, number of participants with available results; Tdap, reduced-antigen-content diphtheria-tetanus-acellular
pertussis vaccine.
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countries,mainly inwhite Caucasian pregnantwomen, hence the data
may not be generalizable to other settings (low- and middle-income
countries)or ethnicities.Also, thestudy results refer tohealthywomen
with and infants born from low-risk pregnancies, with appropriate
access to health care services and to childhood immunizations.Some of the main strengths of our study include its single-blind,
randomized, placebo-controlled design, its large sample size,
ensuring high power to conclude on the primary objective, the high
retention of participants (with 96% of women completing the study
and 84% being included in the ATP analysis) and the high compli-
ance in returning diary cards (>96%).
Table 7
Solicited and unsolicited adverse events after the pregnancy and post-delivery doses (total vaccinated cohort).
Pregnancy dose Post-delivery dose
Tdap group (N = 335)
(received Tdap)
Control group (N = 343a)
(received placebo)
Tdap group
(N = 324)
(received placebo)
Control group
(N = 330a)
(received Tdap)
Adverse event n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
Solicited local AEs (8 days post-vaccination)
Pain
Any 289 86.3 (82.1–89.8) 50 14.6 (11.0–18.8) 41 12.7 (9.2–16.8) 207 62.7 (57.3–68.0)
Grade 3 7 2.1 (0.8–4.3) 0 0.0 (0.0–1.1) 2 0.6 (0.1–2.2) 14 4.2 (2.3–7.0)
Redness
Any 96 28.7 (23.9–33.8) 44 12.8 (9.5–16.8) 34 10.5 (7.4–14.4) 98 29.7 (24.8–34.9)
>50 mm 3 0.9 (0.2–2.6) 0 0.0 (0.0–1.1) 0 0.0 (0.0–1.1) 3 0.9 (0.2–2.6)
Swelling
Any 84 25.1 (20.5–30.1) 12 3.5 (1.8–6.0) 17 5.2 (3.1–8.3) 87 26.4 (21.7–31.5)
>50 mm 3 0.9 (0.2–2.6) 0 0.0 (0.0–1.1) 0 0.0 (0.0–1.1) 4 1.2 (0.3–3.1)
Solicited general AEs (8 days post-vaccination)
Fatigue
Any 146 43.6 (38.2–49.1) 124 36.3 (31.2–41.6) 130 40.1 (34.7–45.7) 153 46.2 (40.8–51.8)
Grade 3 6 1.8 (0.7–3.9) 5 1.5 (0.5–3.4) 24 7.4 (4.8–10.8) 36 10.9 (7.7–14.7)
GI symptoms
Any 60 17.9 (14.0–22.4) 52 15.2 (11.6–19.5) 32 9.9 (6.9–13.7) 42 12.7 (9.3–16.8)
Grade 3 3 0.9 (0.2–2.6) 3 0.9 (0.2–2.5) 6 1.9 (0.7–4.0) 5 1.5 (0.5–3.5)
Headache
Any 83 24.8 (20.2–29.8) 78 22.8 (18.5–27.6) 75 23.1 (18.7–28.1) 78 23.6 (19.1–28.5)
Grade 3 4 1.2 (0.3–3.0) 3 0.9 (0.2–2.5) 5 1.5 (0.5–3.6) 4 1.2 (0.3–3.1)
Fever
Any 4 1.2 (0.3–3.0) 3 0.9 (0.2–2.5) 15 4.6 (2.6–7.5) 30 9.1 (6.2–12.7)
>39.0 C 0 0.0 (0.0–1.1) 0 0.0 (0.0–1.1) 3 0.9 (0.2–2.7) 1 0.3 (0.0–1.7)
Unsolicited AEs (31 days post-vaccination)
(N = 341) (N = 346) (N = 336) (N = 342)
Any 132 38.7 (33.5–44.1) 123 35.5 (30.5–40.8) 103 30.7 (25.8–35.9) 110 32.2 (27.2–37.4)
Grade 3 23 6.7 (4.3–9.9) 10 2.9 (1.4–5.3) 17 5.1 (3.0–8.0) 6.1 (3.8–9.2)
Vaccine-related 8 2.3 (1.0–4.6) 11 3.2 (1.6–5.6) 5 1.5 (0.5–3.4) 21 2.0 (0.8–4.2)
Abbreviations: AE, adverse event; CI, confidence interval; GI, gastrointestinal; N, number of vaccinated participants (for unsolicited AEs) or number of participants with documented
dose (solicited AEs); n/%, number/percentage of participants reporting the event at least once; Tdap, reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine.
a For solicited general AEs, N = 342 for the pregnancy dose and N = 331 for the post-delivery dose. Grade 3 pain was defined as significant pain at rest or pain preventing
normal activities; fatigue, GI symptoms, headache and unsolicited AEs were considered grade 3 if they prevented normal activities.
Table 6
Pregnancy outcomes, pregnancy-/neonate-related adverse events of interest and characteristics of infants at birth (total vaccinated cohort).
Tdap group (N = 341) Control group (N = 346)
Outcome n % (95% CI) n % (95% CI)
Pregnancy outcomesa
Live infant no apparent congenital anomaly 332 97.4 (95.0–98.8) 337 97.4 (95.1–98.8)
Live infant congenital anomalyb 9 2.6 (1.2–5.0) 8 2.3 (1.0–4.5)
Lost to follow-up 0 0.0 (0.0–1.1) 1 0.3 (0.0–1.6)
Pregnancy-/neonate related adverse events of interestc
Intrauterine growth restriction/poor fetal growth 5 1.5 (0.5–3.4) 2 0.6 (0.1–2.1)
Pre-eclampsia 1 0.3 (0.0–1.6) 5 1.4 (0.5–3.3)
Pregnancy-related hypertension 4 1.2 (0.3–3.0) 5 1.4 (0.5–3.3)
Premature labor 13 3.8 (2.0–6.4) 11 3.2 (1.6–5.6)
Premature rupture of membranes 13 3.8 (2.0–6.4) 15 4.3 (2.4–7.0)
Premature uterine contractions 2 0.6 (0.1–2.1) 3 0.9 (0.2–2.5)
Preterm birth 11 3.2 (1.6–5.7) 9 2.6 (1.2–4.9)
Preterm premature rupture of membranes 4 1.2 (0.3–3.0) 7 2.0 (0.8–4.1)
Small for gestational age 2 0.6 (0.1–2.1) 2 0.6 (0.1–2.1)
Vaginal or intrauterine hemorrhage 9 2.6 (1.2–5.0) 10 2.9 (1.4–5.3)
Infant characteristics at birth Value ± SD Value ± SD
Mean weight, kg 3.3 ± 0.5 3.4 ± 0.4
Mean head circumference, cm 34.6 ± 1.7 34.8 ± 1.3
Mean Apgar score 1 min 8.8 ± 1.1 8.8 ± 1.2
Mean Apgar score 5 min 9.5 ± 0.6 9.5 ± 0.6
Abbreviations: CI, confidence interval; N, number of vaccinated participants per group; n/%, number/percentage of participants reporting the specified event; SD, standard
deviation; Tdap, reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine.
a There were no stillbirths or elective terminations.
b Additional congenital anomalies were reported in the follow-up studies (NCT02422264 and NCT02853929) if they became apparent after the current study ended.
c No maternal or neonatal deaths, gestational diabetes, eclampsia, neonatal hypoxic-ischemic encephalopathy, failure to thrive or growth deficiencies were observed in
either of the groups.
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our current study, persistence of pertussis antibodies to
2–3 months of age and the effect of maternal Tdap immunization
on infant immune responses to and safety of primary and booster
DTaP vaccination in the child’s first 18 months of life are assessed
in two follow-up studies (NCT02422264 [45] and NCT02853929).5. Conclusion
This placebo-controlled randomized trial, currently the largest
on pertussis vaccination during pregnancy, brings additional evi-
dence for maternal pertussis immunization providing high levels
of transplacental antibodies to infants for protection against per-
tussis disease during the vulnerable newborn period. This study
adds a substantial amount of high-quality safety data on preg-
nancy outcomes and pregnancy-/neonate-related AEs. Our data
support the recommendation for routine Tdap immunization in
pregnancy to improve protection of infants against pertussis dis-
ease prior to primary infant immunization.6. Contributors
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